EPSRC logo

Details of Grant 

EPSRC Reference: EP/H031111/2
Title: Innovative targets for circadian drug discovery: REV-ERBalpha and RORalpha
Principal Investigator: Tomkinson, Professor NCO
Other Investigators:
Researcher Co-Investigators:
Project Partners:
GlaxoSmithKline (Global) GlaxoSmithKline plc (GSK)
Department: Pure and Applied Chemistry
Organisation: University of Strathclyde
Scheme: Standard Research
Starts: 01 July 2011 Ends: 31 December 2014 Value (£): 1,210,241
EPSRC Research Topic Classifications:
Biological & Medicinal Chem. Chemical Biology
Medical science & disease
EPSRC Industrial Sector Classifications:
Healthcare Pharmaceuticals and Biotechnology
Related Grants:
Panel History:  
Summary on Grant Application Form
Humans are rhythmic beings, with daily sleep/wake cycles affecting almost every aspect of physiology and behaviour. Our master circadian clock is known to reside in the suprachiasmatic nuclei (SCN) of the hypothalamus. Via multiple pathways, output from the SCN synchronizes peripheral oscillators throughout the body. The discovery of the molecular components of the core clock has provided new insight into the link between circadian biology and chronic diseases, but has not been exploited for drug discovery. With this work we will prepare chemical probes for the clock proteins REV-ERBalpha and RORalpha, characterise their activity in models of inflammation, and deliver lead optimised molecules for clinical development.
Key Findings
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Potential use in non-academic contexts
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Impacts
Description This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Summary
Date Materialised
Sectors submitted by the Researcher
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Project URL:  
Further Information:  
Organisation Website: http://www.strath.ac.uk